T Type Calcium Channel Antagonists Antagonists Pipeline Insight, 2022 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across T Type Calcium Channel Antagonists Antagonists development.

T Type Calcium Channel Antagonists Antagonists Pipeline Insight | T Type Calcium Channel Antagonists Antagonists Mechanism of Action Insight

DelveInsight&rsquo;s, &ldquo;T Type Calcium Channel Antagonists - Pipeline Insight, 2025,&rdquo; report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T Type Calcium Channel Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>T Type Calcium Channel Antagonists Understanding</h2>
T Type Calcium Channel Antagonists: Overview
T-type calcium channels are low-voltage activated calcium channels. T-type calcium channels are predominantly found in neurons but have been found in other cells including cardiac myocytes, pacemaker cells, glial cells, fibroblasts, osteoblasts, retinal cells, and adrenocortical cells. These channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. T-type Ca2+ channel blockers are capable of interrupting certain pathological hypertrophic signaling pathways, including calcineurin-mediated nuclear factor of activated T cells&ndash;3 activation. Trimethadione (TMO) is a T-type calcium channel blocker approved by the FDA as an anticonvulsant for absence seizures.
<h2>Report Highlights</h2>
The companies and academics are working to assess challenges and seek opportunities that could influence T Type Calcium Channel Antagonists R&amp;D. The therapies under development are focused on novel approaches for T Type Calcium Channel Antagonists.
<h2>T Type Calcium Channel Antagonists Emerging Drugs Chapters</h2>
This segment of the T Type Calcium Channel Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
T Type Calcium Channel Antagonists Emerging Drugs
&nbsp;
NBI 827104: Neurocrine Biosciences
NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker. Neurocrine Biosciences acquired the exclusive rights to NBI-827104 from Idorsia. The drug is in Phase II clinical studies for essential tremor and Epileptic Encephalopathy with Continuous Spike-and-Wave during Sleep (EE-CSWS). Neurocrine Biosciences has received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration for NBI-827104 in EE-CSWS.
&nbsp;
PRAX-944: Praxis Precision Medicines
PRAX 944 is an oral, small molecule based T-type calcium channel blocker. The drug is in Phase II clinical developmental studies for the treatment of essential tremor. PRAX-944 is suitable for potential development across a wide-range of indications in psychiatry and neurology.
Further product details are provided in the report&hellip;&hellip;..
<h2>T Type Calcium Channel Antagonists: Therapeutic Assessment</h2>
This segment of the report provides insights about the different T Type Calcium Channel Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
<ul>
<li>Major Players working on T Type Calcium Channel Antagonists</li>
</ul>
There are approx. 10+ key companies which are developing the T Type Calcium Channel Antagonists. The companies which have their T Type Calcium Channel Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Neurocrine Biosciences.
<h2>Phases</h2>
DelveInsight&rsquo;s report covers around 10+ products under different phases of clinical development like
<ul>
<li>Late-stage products (Phase III and</li>
<li>Mid-stage products (Phase II and</li>
<li>Early-stage products (Phase I/II and Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
<li>Route of Administration</li>
</ul>
&nbsp;
T Type Calcium Channel Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 
<ul>
<li>Infusion</li>
<li>Intradermal</li>
<li>Intramuscular</li>
<li>Intranasal</li>
<li>Intravaginal</li>
<li>Oral</li>
<li>Parenteral</li>
<li>Subcutaneous</li>
<li>Topical</li>
<li>Molecule Type</li>
</ul>
&nbsp;
Products have been categorized under various Molecule types such as
<ul>
<li>Vaccines</li>
<li>Monoclonal Antibody</li>
<li>Peptides</li>
<li>Polymer</li>
<li>Small molecule</li>
<li>Product Type</li>
</ul>
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>T Type Calcium Channel Antagonists: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T Type Calcium Channel Antagonists therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T Type Calcium Channel Antagonists drugs.
<h2>T Type Calcium Channel Antagonists Report Insights</h2>
<ul>
<li>T Type Calcium Channel Antagonists Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>T Type Calcium Channel Antagonists Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing T Type Calcium Channel Antagonists drugs?</li>
<li>How many T Type Calcium Channel Antagonists drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for T Type Calcium Channel Antagonists?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the T Type Calcium Channel Antagonists therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for T Type Calcium Channel Antagonists and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>

Introduction
Executive Summary
T Type Calcium Channel Antagonists: Overview
<ul>
<li>Structure</li>
<li>Mechanism of Action&nbsp;</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
</ul>
T Type Calcium Channel Antagonists &ndash; DelveInsight&rsquo;s Analytical Perspective
In-depth Commercial Assessment
<ul>
<li>T Type Calcium Channel Antagonists companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends</li>
</ul>
T Type Calcium Channel Antagonists Collaboration Deals
<ul>
<li>Company-Company Collaborations (Licensing / Partnering) Analysis</li>
<li>Company-University Collaborations (Licensing / Partnering) Analysis</li>
</ul>
Late Stage Products (Phase III)&nbsp;
<ul>
<li>Comparative Analysis</li>
</ul>
Benidipine/telmisartan: Synokem Pharmaceuticals
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
NBI 827104: Neurocrine Biosciences
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I)&nbsp;
<ul>
<li>Comparative Analysis</li>
</ul>
KBP 5660: Sihuan Pharmaceutical Holdings Group
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Pre-clinical and Discovery Stage Products
<ul>
<li>Comparative Analysis</li>
</ul>
CLX-CNS-04: Cellix Bio
<ul>
<li>Product Description</li>
<li>Research and Development&nbsp;</li>
<li>Product Development Activities&nbsp;</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
T Type Calcium Channel Antagonists Key Companies
T Type Calcium Channel Antagonists Key Products
T Type Calcium Channel Antagonists- Unmet Needs
T Type Calcium Channel Antagonists- Market Drivers and Barriers
T Type Calcium Channel Antagonists- Future Perspectives and Conclusion
T Type Calcium Channel Antagonists Analyst Views
T Type Calcium Channel Antagonists Key Companies
Appendix

T Type Calcium Channel Antagonists - Pipeline Insight, 2025

"T Type Calcium Channel Antagonists Antagonists" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action.